Loading
Rallybio Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 May 2026.
Rallybio Corp: what insiders have been doing
Headquartered in New Haven, United States, Rallybio Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 15 filings signed by 7 insiders.
No insider sold shares on the market over the period. Instead, the filings list 4 purchases totalling €950k, made by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 major shareholder. At €898k, the purchase published on 15 May 2026 by ADAR1 Capital Management, LLC is the largest of the period (1.2% of market cap).
The last purchase on record was published on 15 May 2026, which is 155 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,808 companies, median 19 filings), a count of 15 filings is below the norm. Since 2021, the database holds 8 purchases and 7 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Key facts
Headquarters: New Haven, United States
Source: Wikidata (CC0).
Insider Decl.
37
Thresholds
n/a
Buy Volume
€8M
8 ops. · all time
Sell Volume
€6M
7 ops. · all time
Who traded when
BuySaleADAR1 Capital Management, LLC4 buys
Since the insiders bought
- +19.9%Entry US$14.10 · Close 14 Oct 2026 US$16.91
- -36.7%Entry US$57.52 · Close at T+365 US$36.40
- -51.9%Entry US$187.20 · Close at T+365 US$90.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.72
Analyst consensus
Income statement
RevenueUS$858k
EBITDA-US$33M-3843% margin
Net income-US$9M7051.2% margin
Valuation
PER (trailing)2.1x
P/Book0.9x
Beta-0.71
Balance sheet & cash
Market capUS$88.8M
Total debtUS$176k
Free Cash Flow-US$29.8M
Debt / Equity0%
Profitability & ownership
ROE64.9%
ROA-21.3%
% insiders24.5%
% institutions86.1%
Last declaration on 14 October 2026
Declarations37 total
9,196 shares@ US$7.600.079% mcap63.6% of flowCommon StockSEC:0001193125-26-421747:0
3,562 shares@ US$2.380.0095% mcap7.7% of flowCommon StockSEC:0001193125-26-421747:1
2,062 shares@ US$15.280.035% mcap28.7% of flowCommon StockSEC:0001193125-26-421747:2
3,910 shares@ US$6.080.026% mcap29.3% of flowCommon StockSEC:0001193125-26-420562:0
22,456 shares@ US$6.080.15% mcap100.0% of flowCommon StockSEC:0001193125-26-418051:0
5,000 shares@ US$6.080.033% mcap52.4% of flowCommon StockSEC:0001193125-26-410885:0
3,562 shares@ US$2.380.0095% mcap100.0% of flowCommon StockSEC:0001193125-26-395755:0
3,562 shares@ US$2.380.0096% mcap100.0% of flowCommon StockSEC:0001193125-26-300913:0
100 shares@ US$13.800.0015% mcap0.1% of flowCommon StockSEC:0001104659-26-062883:2
Canonical exit: 13 Aug 2026 (T+90)
75,178 shares@ US$14.001.16% mcap94.6% of flowCommon StockSEC:0001104659-26-062883:1
Canonical exit: 11 Aug 2026 (T+90)
200 shares@ US$13.950.0031% mcap0.3% of flowCommon StockSEC:0001104659-26-062883:3
Canonical exit: 13 Aug 2026 (T+90)
4,081 shares@ US$13.79930.062% mcap5.1% of flowCommon StockSEC:0001104659-26-062883:0
Canonical exit: 11 Aug 2026 (T+90)
2,500 shares0Common StockSEC:0001739410-26-000022:0
5,000 shares@ US$5.21100.0% of flowCommon StockSEC:0000950170-23-008553:0
Canonical exit: 12 Jun 2023 (T+90)
100,000 shares@ US$8.20100.0% of flowCommon StockSEC:0001209191-23-017533:0
▼
Same trade as the filing by 5AM Partners V, LLC, counted once · View ↗
100,000 shares@ US$8.2017.7% of flowCommon StockSEC:0001209191-23-017538:0
99,671 shares@ US$12.5026.8% of flowCommon StockSEC:0001209191-22-034860:0
50,329 shares@ US$12.506.0% of flowCommon StockSEC:0001209191-22-034858:0
▼
Same trade as the filing by Kush Parmar, counted once · View ↗
99,671 shares@ US$12.5012.0% of flowCommon StockSEC:0001209191-22-034858:1
66,447 shares@ US$13.0018.7% of flowCommon StockSEC:0001209191-22-031969:0
33,553 shares@ US$13.004.2% of flowCommon StockSEC:0001209191-22-031966:0
3,000 shares@ US$8.0467.0% of flowCommon StockSEC:0000899243-22-011950:0
Canonical exit: 19 Jun 2022 (T+90)
70,461 shares@ US$13.058.3% of flowCommon StockSEC:0001209191-22-008584:0
25 of 37 declarations
About Rallybio Corp
Rallybio Corp (NASDAQ: RLYB) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, United States. Founded in January 2018, the company was built by a seasoned management team with deep experience in rare-disease drug discovery, development, and commercialization. Rallybio’s strategic identity is that of a focused specialty biotech: rather than pursuing a broad platform across multiple therapeutic franchises, it concentrates on severe rare diseases with substantial unmet medical need. That positioning can be attractive from an R&D efficiency standpoint, but it also means the investment case is highly dependent on a small number of clinical programs and execution milestones.
Rallybio’s pipeline has been centered on candidates addressing complement dysregulation, hematology, and maternal-fetal health. Among the company’s most visible programs have been RLYB212, a novel human monoclonal anti-HPA-1a antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, a once-weekly, low-volume subcutaneous inhibitor of complement component 5 (C5) for complement-mediated diseases. The company has also emphasized portfolio prioritization, including a narrowing of resources toward its most advanced assets. For an investor, that is a sign of discipline, but also a reminder that Rallybio remains a pre-commercial biotech with limited operating history and no approved products.
Read moreShow less
In competitive terms, Rallybio sits in the small-cap rare-disease biotech universe, where differentiation comes from scientific novelty, clinical proof-of-concept, and the ability to secure partnerships or financing. It does not yet compete as a marketed-product company; instead, its valuation is driven by pipeline optionality and the probability of future clinical success. The company’s geographic footprint is largely U.S.-based, with core operations in New Haven, Connecticut, and a business model focused on research, development, and regulatory advancement rather than manufacturing scale or a broad commercial network.
Recent company news has been especially important for the investment narrative. In March 2025, Rallybio reported full-year 2024 results and stated that its cash, cash equivalents, and marketable securities were sufficient to fund operations into the second half of 2026. More recently, in March 2026, Rallybio announced a merger agreement with Candid Therapeutics. Under the proposed transaction, the combined company is expected to operate as Candid Therapeutics and trade on Nasdaq under the ticker CDRX, subject to customary closing conditions and approvals. For investors following SEC Form 4 insider activity, Rallybio remains a catalyst-driven biotech story where insider transactions should be viewed in the context of clinical timing, balance-sheet runway, and transaction outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
